Sol-Gel Technologies Ltd.

SLGL
About the company

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.

Country: IsraelPrice: $55.12Market Cap: $180.5M

Investment snapshot

6%positive consensus
Scored 1d ago

Positive

1

BUY / PASS

Neutral / negative

3 / 12

NEUTRAL / FAIL

Median fair value

$2.67

-95.2% vs price

Models with upside

0 / 17

Positive margin of safety

Key risk

All 13 investors flag SLGL's valuation

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2328 (Top 75.2%)PASSFAILFAILFAILFAILFAILFAILFAILNEUTRALNEUTRALFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/A-2962.2%N/AN/AN/A-1457.1%N/AN/AN/AN/AN/AN/A
Financial Basis

Annual history · FY 2025

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025 · Market data at 2026-11-01

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-03-19

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✗ 28▾

      All 13 investors flag SLGL's valuation

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio6.7x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-4.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-4.4%, ROC=-76.1%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)476.9x
      ✗Dreman< 8x
      Price / Book Value per Share6.7x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-3.9%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=0.2%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=6.7x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share558.4x
      ✗Ackman<= 25
      Price vs. Trailing Low1060% of trailing low ($5.20)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-3.40%; #3712/6340 (top 58.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.1264; #4597/6449 (top 71.3%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per Share6.73x
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change
      ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.1074; #4299/5247 (top 81.9%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization+0.15%; #2512/4519 (top 55.6%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-26.37%; #4261/6202 (top 68.7%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Valuation models0% pass✗ 2▾

      SLGL overvalued: all 2 models price fair value below $55.12 (median $2.67)

      Munger fair value$1.80
      ✗Munger-2962.2% margin vs $55.12
      Ackman fair value$3.54
      ✗Ackman-1457.1% margin vs $55.12
    • Profitability6% pass✓ 5✗ 30▾

      15 of 16 flag SLGL's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)5/12 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)1/12 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-32.7%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-38.9% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-6.1M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-26.9%
      ✗Lynch> 15%
      EBIT / Enterprise Value-4.4%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-4.4%, ROC=-76.1%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-20.48%
      ✗PiotroskiROA > 0
      ROA Change YoY-29.52% -> -20.48% (delta: +9.04%)
      ✓PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=1.08%, ROA=-20.48%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-26.9%
      ✗Dreman> 12%
      Margin of SafetyP/B=6.7x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-44.7% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic Value
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency1/11 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-38.9%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-26.9%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-1885.8% (2023) -> -38.9% (2025)
      ✓TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendrevenue up, operating margin -1885.8% -> -38.9%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-3.40%; #3712/6340 (top 58.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-26.86%; #3840/5226 (top 73.5%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.2085; #4271/5884 (top 72.6%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR-46.8% over 5 years
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years4/10 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Verdicts7% pass✓ 1✗ 13▾

      Split decision: 12 FAIL · 3 NEUTRAL · 1 PASS

      Overall verdict
      ✗GrahamFAIL (1/9)✗BuffettFAIL (1/9)✗LynchFAIL (2/7)✗GreenblattRank #2328✓PiotroskiPASS (F-Score 5)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (1/6)✗MarksFAIL (0/5)✗AckmanFAIL (2/9)✗TempletonFAIL (2/8)•SleepNEUTRAL (4/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (2/6)✗SchlossFAIL (1/7)•OshaughnessyNEUTRAL (Not ranked)
    • Debt & Leverage8% pass✓ 3✗ 12▾

      11 of 12 flag SLGL's debt & leverage — Graham, Buffett, Lynch +8 more

      LT Debt vs Net Current Assets
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest Coverage
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity
      ✗Lynch< 0.33
      Cash - Long-term Debt
      ✗LynchPositive preferred
      LT Debt / Total Assets Change0.00% -> 0.00%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities4.37
      ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity
      ✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00x
      Debt Levels
      ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDA
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity
      ✗Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)
      ✗AsnessTop 30% of eligible cross-section
    • Growth13% pass✓ 4✗ 9▾

      7 of 8 flag SLGL's growth — Graham, Lynch, Dreman +4 more

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthN/A (no inventory)
      ✓LynchInventory growth < Revenue growth
      EPS Growth Direction
      ✗DremanPositive over recent years
      EPS CAGR-32.9% CAGR over 6 years
      ✗Dreman> 5% annualized
      Positive Net Income Frequency1/11 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth68.0%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendrevenue up, operating margin -1885.8% -> -38.9%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR17.2%
      ✓SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR-46.8% over 5 years
      ✗Neff7%-20% annualized
    • Efficiency25% pass✓ 3✗ 8▾

      6 of 8 flag SLGL's efficiency — Buffett, Greenblatt, Piotroski +3 more

      Current Ratio4.37
      ✓Graham>= 2.0
      ROIC (3-5 yr avg)-328.2%
      ✗Buffett> 10%
      ROIC - WACC-338.2%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-76.1%
      ✗Greenblatt> 25%
      Current Ratio Change YoY5.92 -> 4.37
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.32x -> 0.65x
      ✓PiotroskiImproved YoY
      Current Assets / Current Liabilities4.37
      ✓Dreman> 1.5
      Return on Invested Capital
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=unavailable; FY2025: ROIC=unavailable
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROIC
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)
      ✗SleepROIC > 12% in a majority of years
    • Cash Flow30% pass✓ 4✗ 8▾

      7 of 10 flag SLGL's cash flow — Buffett, Dreman, Pabrai +4 more

      Free Cash Flow Proxy$-6.1M
      ✗BuffettPositive and growing
      FCF Positive and Growing$0.3M
      ✓LynchPositive and growing
      Operating Cash Flow$0.3M
      ✓PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=1.08%, ROA=-20.48%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)476.9x
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=0.2%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive1/11 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap0.2%
      ✗Ackman>= 4%
      Price / FCF per Share558.4x
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency1/11 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$0.3M
      ✓Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization+0.15%; #2512/4519 (top 55.6%)
      ✗OshaughnessyTop 10% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Pharmaceutical Products
    SIC Sector: Chemicals & Pharmaceuticals
    Size: Micro Cap($180.5M)
    Revenue: $19.4M+68.0% YoY
    Net Income: $6.1M+42.1% YoY

    Financial Snapshot

    Operating Margin-38.9%
    Return on Equity-26.9%
    Debt / Equity--
    Current Ratio4.37
    EPS (Diluted)$-2.19
    Shares Retired−0.0% / −0.0% 2y

    Shareholder Return

    Fiscal 2025

    Issued 0.0% of shares last year, 0.0% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    MetricFY 2025
    Sources
    • 20-F · 2026-03-19
    FY 2024
    Sources
    • 20-F · 2025-04-29
    FY 2023
    Sources
    • 20-F · 2024-03-13
    FY 2022
    Sources
    • 20-F · 2023-03-10
    FY 2021
    Sources
    • 20-F · 2022-04-04
    Market Cap$180.5Mcurrent$213.1Mest.$390.0Mest.$1.2Best.$1.6Best.
    Revenue$19.4M↑68%$11.5M↑642%$1.6M↓60%$3.9M↓88%$31.3M
    Operating Income-$7.5M↑37%-$12.0M↑59%-$29.3M↓80%-$16.2M↓648%$3.0M
    Net Income-$6.1M↑42%-$10.6M↑61%-$27.2M↓83%-$14.9M↓563%$3.2M
    EPS (Diluted)$-2.19↓476%$-0.38↑62%$-1.01↓55%$-0.65↓564%$0.14
    Gross Margin—————
    Operating Margin-38.9%↑63%-104.1%↑94%-1885.8%↓351%-418.3%↓4514%9.5%
    ROE-26.9%↑27%-36.7%↑48%-70.5%↓99%-35.4%↓710%5.8%
    Total Debt----------
    Shareholders' Equity$22.8M↓21%$28.9M↓25%$38.6M↓8%$42.2M↓24%$55.6M
    Current Ratio4.37↓26%5.92↓35%9.10↓30%12.93↑165%4.88
    Debt / Equity—————
    Operating Cash Flow$322.0K↑102%-$13.9M↑22%-$17.7M↓87%-$9.5M↓23%-$7.7M
    Free Cash Flow$275.0K↑102%-$13.9M↑22%-$17.9M↓85%-$9.7M↓23%-$7.8M

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Pharmaceutical Products

    SLGL vs Peers — Financial Grading

    Revenue$19.4MBottom 25%
    Net Income$6.1MMedian
    ROE-26.9%Bottom 25%
    D/E—
    Op. Margin-38.9%Bottom 25%
    Curr. Ratio4.37Top 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
    ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
    BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
    BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
    REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
    IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
    NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
    Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11